RYTM vs. ARVN, MORF, AKRO, PLRX, ANNX, ELAN, ROIV, INSM, ASND, and CERE
Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Arvinas (ARVN), Morphic (MORF), Akero Therapeutics (AKRO), Pliant Therapeutics (PLRX), Annexon (ANNX), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Ascendis Pharma A/S (ASND), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas (NASDAQ:ARVN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability.
Rhythm Pharmaceuticals received 104 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 65.71% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.40% of users gave Arvinas an outperform vote.
Arvinas has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.
Arvinas has a net margin of -185.09% compared to Arvinas' net margin of -297.91%. Rhythm Pharmaceuticals' return on equity of -64.79% beat Arvinas' return on equity.
Rhythm Pharmaceuticals has lower revenue, but higher earnings than Arvinas. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Arvinas currently has a consensus target price of $61.13, suggesting a potential upside of 130.87%. Rhythm Pharmaceuticals has a consensus target price of $54.33, suggesting a potential upside of 37.52%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Arvinas is more favorable than Rhythm Pharmaceuticals.
95.2% of Arvinas shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Arvinas had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Arvinas and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.41 beat Arvinas' score of 0.60 indicating that Arvinas is being referred to more favorably in the media.
Summary
Arvinas beats Rhythm Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Rhythm Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rhythm Pharmaceuticals Competitors List
Related Companies and Tools
